202 related articles for article (PubMed ID: 26348867)
1. Bone health management of Australian breast cancer survivors receiving hormonal therapy.
Roberts R; Miller M; O'Callaghan M; Koczwara B
Intern Med J; 2015 Nov; 45(11):1182-5. PubMed ID: 26348867
[TBL] [Abstract][Full Text] [Related]
2. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
Parton M; Smith IE
J Clin Oncol; 2008 Feb; 26(5):745-52. PubMed ID: 18258982
[No Abstract] [Full Text] [Related]
3. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Santen RJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.
Ramin C; May BJ; Roden RBS; Orellana MM; Hogan BC; McCullough MS; Petry D; Armstrong DK; Visvanathan K
Breast Cancer Res; 2018 Nov; 20(1):134. PubMed ID: 30424783
[TBL] [Abstract][Full Text] [Related]
5. Exemestane or tamoxifen?
Ueda M; Toji E; Noda S
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
[No Abstract] [Full Text] [Related]
6. [Effect of aromatase inhibitors on bone metabolism].
Folkestad L; Bjerregaard JK; Bjarnason NH; Brixen KT
Ugeskr Laeger; 2007 May; 169(19):1774-9. PubMed ID: 17537350
[TBL] [Abstract][Full Text] [Related]
7. Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Gibson K; O'Bryant CL
J Oncol Pharm Pract; 2008 Sep; 14(3):139-45. PubMed ID: 18719068
[TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
[TBL] [Abstract][Full Text] [Related]
9. Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy.
Rugo HS
Clin Breast Cancer; 2007 Jul; 7 Suppl 1():S21-8. PubMed ID: 17683650
[TBL] [Abstract][Full Text] [Related]
10. Osteopenia and osteoporosis in women with breast cancer.
Ramaswamy B; Shapiro CL
Semin Oncol; 2003 Dec; 30(6):763-75. PubMed ID: 14663777
[TBL] [Abstract][Full Text] [Related]
11. Emerging bone health issues in women with breast cancer in Hawai'i.
Carney JF; Davis J
Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
[TBL] [Abstract][Full Text] [Related]
12. Cancer treatment-induced bone loss in breast and prostate cancer.
Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
[TBL] [Abstract][Full Text] [Related]
13. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of dual-energy X-ray absorptiometry plus antiresorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.
Sowa PM; Downes MJ; Gordon LG
J Bone Miner Metab; 2017 Mar; 35(2):199-208. PubMed ID: 26969395
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors and bone health in women with breast cancer.
Chien AJ; Goss PE
J Clin Oncol; 2006 Nov; 24(33):5305-12. PubMed ID: 17114665
[No Abstract] [Full Text] [Related]
17. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
Safra T; Bernstein-Molho R; Greenberg J; Pelles-Avraham S; Stephansky I; Sarid D; Inbar MJ; Stemmer SM; Geffen DB
Oncology; 2011; 81(5-6):298-305. PubMed ID: 22156381
[TBL] [Abstract][Full Text] [Related]
18. The effect of aromatase inhibitors on bone metabolism.
Folkestad L; Bjarnason NH; Bjerregaard JK; Brixen K
Basic Clin Pharmacol Toxicol; 2009 Jan; 104(1):3-10. PubMed ID: 19152547
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant treatment of breast cancer with exemestane.
Tanvetyanon T
N Engl J Med; 2004 Jul; 351(1):100-2; author reply 100-2. PubMed ID: 15237463
[No Abstract] [Full Text] [Related]
20. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]